It doesn't happen every day, but surprisingly positive clinical trial results can more than double your money in minutes. Shares of Karuna Therapeutics (NASDAQ: KRTX) recently increased more than sevenfold after investors learned that its potential new schizophrenia drug, KarXT, produced a measurable benefit with a safety profile that was better than anyone was expecting.
Can Karuna Therapeutics stock keep climbing, or was the recent run-up just a flash in the pan? There are a lot of ins and outs to consider. Let's see how they add up.
Image source: Getty Images.